Investigation of Acupoint in Irritable Bowel Syndrome Based on Biological Characteristics - Trial NCT06365801
Access comprehensive clinical trial information for NCT06365801 through Pure Global AI's free database. This phase not specified trial is sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
The Third Affiliated hospital of Zhejiang Chinese Medical University
Timeline & Enrollment
N/A
Apr 01, 2024
Dec 01, 2025
Primary Outcome
Pain sensitivity,Thermal radiation characteristics,Microcirculation characteristics,Electrical characteristics,Biological ultra-weak luminescence
Summary
Irritable bowel syndrome (IBS) is a common functional disorder of the digestive system
 characterized by recurrent abdominal pain associated with bowel movements or changes in bowel
 habits. Although there are reviews and guidelines for treating IBS, the complexity and
 diversity of IBS manifestations make treatment difficult. By detecting and exploring the
 biological characteristics presented by the relevant meridian point reaction, this project
 clarified the specificity and regularity of the connection between the acupoint and the
 Zangfu reflected by this phenomenon, and conducted correlation analysis based on the
 intestinal flora, tryptophan metabolite levels and related scales of patients with IBS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06365801
Non-Device Trial